Proteome analysis of cerebrospinal fluid in healthy beagles and canine encephalitis.

We performed proteomics analysis of the cerebrospinal fluid (CSF) of healthy dogs and dogs with meningoencephalitis of unknown etiology (MUE). By comparing two-dimensional electrophoreses (2DE), an upregulated spot was found in MUE dogs. This protein was identified as a neuron-specific enolase (NSE) by analysis with MALDI-TOF mass spectrometry. In comparing dot blots using an antibody against NSE, the NSE levels in the CSF of MUE dogs was significantly higher than that of the controls. NSE is a diagnostic marker of neuroendocrine tumors, brain injury and spinal cord trauma in humans. It seems that the NSE concentration in the CSF is increased by cellular destruction in canine encephalitis. Though elevation of NSE may not be specific in canine encephalitis because the NSE level was increased in other CNS diseases, further study including measurement with serum is necessary.

[1]  M. Groschup,et al.  A comprehensive proteome map of bovine cerebrospinal fluid , 2009, Proteomics.

[2]  Zhaoyu Qin,et al.  Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients , 2009, Molecular vision.

[3]  Yazhou Cui,et al.  Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barré Syndrome by a proteomical approach , 2009, Molecular Biology Reports.

[4]  A. Hosman,et al.  Biomarkers in spinal cord injury , 2009, Spinal Cord.

[5]  Zhe-yu Chen,et al.  Comparative Proteomics Analysis of Cerebrospinal Fluid of Patients with Guillain–Barré Syndrome , 2008, Cellular and Molecular Neurobiology.

[6]  D. Gambi,et al.  Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis , 2008, Journal of Neuroimmunology.

[7]  S. Süssmuth,et al.  Proteome analysis of cerebrospinal fluid in Guillain–Barré syndrome (GBS) , 2007, Journal of Neuroimmunology.

[8]  T. Arai,et al.  Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: Possible use for assessment of a therapeutic regimen , 2007, Brain Research.

[9]  M. Zarfoss,et al.  Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs. , 2006, The Journal of small animal practice.

[10]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[11]  Kelvin H Lee,et al.  Towards two‐dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual , 2004, Electrophoresis.

[12]  V. Selaković.  Neuron-specific enolase in cerebrospinal fluid and plasma of patients with acute ischemic brain disease. , 2003, Medicinski pregled.

[13]  G. Borm,et al.  Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. , 1992, Clinical chemistry.

[14]  S. Oishi,et al.  Elevated serum neuron‐specific enolase in patients with malignant pheochromocytoma , 1988, Cancer.

[15]  K. Hashimoto,et al.  Serum neuron-specific enolase as a marker useful for monitoring the effectiveness of therapy in patients with neuroblastoma--as compared with urinary catecholamine metabolites. , 1986, The Tohoku journal of experimental medicine.

[16]  P. Marangos,et al.  Severe head trauma and the changes of concentration of neuron-specific enolase in plasma and in cerebrospinal fluid. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[17]  J. Minna,et al.  SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER , 1982, The Lancet.

[18]  C. Merril,et al.  Two-dimensional gel electrophoresis of cerebrospinal fluid proteins. , 1980, Clinical chemistry.

[19]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.